DSGN Design Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1807120 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-9.8%
TTM EPS YoY-0.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-36.9%
ROA-34.6%
ROIC (approx.)-35.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets6.7%
Debt / equity0.00x
Current ratio16.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M |
| SG&A expense | $20.34M | $18.03M | $21.13M | $18.98M | $11.05M |
| Operating income | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M |
| EBITDA | -$78.84M | -$61.79M | -$77.65M | -$67.19M | -$35.70M |
| EPS (basic) | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 |
| EPS (diluted) | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 |
| Weighted avg. shares (diluted) | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M |
| Balance sheet | |||||
| Cash & equivalents | $16.86M | $22.56M | $21.20M | $26.50M | $298.57M |
| Short-term investments | $202.99M | $222.91M | $260.60M | $303.89M | $85.50M |
| Current assets | $223.78M | $248.04M | $284.58M | $335.12M | $385.44M |
| PP&E, net | $981,000 | $1.41M | $1.69M | $1.95M | $1.51M |
| Total assets | $226.20M | $252.09M | $289.64M | $341.14M | $390.56M |
| Current liabilities | $13.05M | $8.46M | $9.62M | $10.78M | $5.28M |
| Total liabilities | $13.70M | $10.00M | $11.96M | $13.83M | $8.43M |
| Shareholders' equity | $212.50M | $242.10M | $277.69M | $327.31M | $382.13M |
| Shares outstanding | 60.40M | 56.75M | 56.47M | 55.90M | 55.44M |
| Cash flow statement | |||||
| Operating cash flow | -$54.36M | -$43.10M | -$58.56M | -$51.32M | -$29.38M |
| Capital expenditure | $193,000 | $340,000 | $256,000 | $918,000 | $1.54M |
| Free cash flow | -$54.55M | -$43.45M | -$58.82M | -$52.23M | -$30.91M |
| Investing cash flow | $22.91M | $43.95M | $52.54M | -$220.99M | -$53.64M |
| Financing cash flow | $25.74M | $513,000 | $724,000 | $235,000 | $379.21M |
| Depreciation & amortization | $622,000 | $596,000 | $537,000 | $406,000 | $129,000 |
| Stock-based compensation | $14.55M | $13.07M | $13.09M | $10.93M | $4.69M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.